EMA starts review of Enhertu for HER2+ gastric cancer

The EMA has started its review of AstraZeneca and Daiichi Sankyo's Enhertu for a second indication, as a second-line treatment for HER2-positive gastric cancer.

European regulators back Blueprint's Ayvakyt for stomach tum...

European regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain mutations.

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cance...

With an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now looks like it may be able to add lung, stomach and colorec

Blueprint pays the price of Ayvakit phase 3 miss as FDA reje...

Blueprint gets first approval as FDA backs stomach cancer dr...

US biotech Blueprint Medicines has its first approved drug, after the FDA backed its oncology drug Ayvakit for a certain kind of stomach cancer.

Merck KGaA/Pfizer's Bavencio fails in stomach cancer trial

Merck KGaA and Pfizer’s cancer immunotherapy Bavencio has disappointed in a hard to treat late-stage gastric cancer trial, failing to extend survival compared to chemotherapy.